Clinical Trials Study
Copyright ©The Author(s) 2021.
World J Gastroenterol. Feb 21, 2021; 27(7): 654-665
Published online Feb 21, 2021. doi: 10.3748/wjg.v27.i7.654
Table 1 Preoperative characteristics

LT group (n = 43)
PSLT group (n = 41)
P value
Gender (male/female)27/1628/130.651
Age, yr49.2 ± 12.852.7 ± 13.10.219
Indication for transplantation
Hepatitis B cirrhosis19210.662
Hepatic malignancy1080.792
Alcoholic cirrhosis860.772
Autoimmune liver disease230.672
etc.43> 0.99
MELD score at transplantation19.4 ± 4.920.7 ± 4.60.214
PreOP biology
Total bilirubin (μmol/L)133.0 ± 106.9128.5 ± 97.20.841
Serum creatinine (μmol/L)96.1 ± 72.682.6 ± 66.30.377
INR1.6 ± 0.61.7 ± 0.60.447
Plasma ammonia (μmol/L)59.7 ± 21.557.6 ± 23.40.669
PreOP platelet count, 103/mm338.6 ± 14.736.9 ± 14.10.590
PreOP spleen volume, cm31665 ± 6111711 ± 6820.745
PreOP PV flow, cm/s12.4 ± 3.911.8 ± 3.70.472
PreOP HA flow, cm/s40.3 ± 22.140.9 ± 21.70.453
Table 2 Donors’ characteristics

LT group (n = 43)
PSLT group (n = 41)
P value
Gender (male/female)31/1228/13> 0.99
Age, yr42.6 ± 16.344.5 ± 15.90.665
Cause of death
Cerebral trauma2422> 0.99
Cerebrovascular accident1080.792
Brain tumor (glioma)450.735
Hypoxic brain injury230.672
etc.33> 0.99
ICU stay, d2.71 ± 2.052.83 ± 2.240.798
Table 3 Operative characteristics

LT group (n = 43)
PSLT group (n = 41)
P value
Operating time, h6.8 ± 0.98.6 ± 1.3< 0.001
Time for PS1.8 ± 0.3
Blood loss, mL349.4 ± 116.9440.8 ± 141.30.002
During PS85.6 ± 79.2
PostOP HA flow, cm/s42.6 ± 11.449.3 ± 13.60.016
PostOP PV flow, cm/s47.6 ± 14.142.7 ± 13.80.022
Weight of PS, g 787 ± 371.4
Percentage of PS, (n)
Half of spleen23
Third of spleen18
Table 4 Postoperative complications, n (%)

LT group (n = 43)
PSLT group (n = 41)
P value
Postoperative hypersplenism22 (51.1)2 (4.8)< 0.001
Recurrent ascites8 (18.6)1 (2.4)0.029
Reoperation due to post-op bleeding2 (4.6)3 (7.3)0.672
Postoperative pulmonary infection5 (11.6)4 (9.7)> 0.99
Post-op thrombosis1 (2.3)1 (2.4)> 0.99
Splenic arterial steal syndrome4 (9.3)00.116
Two-stage splenic embolization17 (39.5)0< 0.001
Further splenectomy6 (13.9)00.026